Publications by authors named "Sonya A Reid"
Article Synopsis
- Immunotherapy has shown promise in improving survival rates for triple-negative breast cancer (TNBC), but better biomarkers are needed to identify patients who will benefit the most from it.
- A study analyzed data from the Carolina Breast Cancer Study, focusing on racial differences in MHC-I and MHC-II expression in tumors, revealing that Black participants have a higher incidence of TNBC and specific tumor characteristics.
- The results indicated that Black women exhibited significantly higher levels of MHC-I and MHC-II expression in HR+/HER2- tumors, highlighting the need for diverse patient representation in future immunotherapy trials.
Background: In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the pre-clinical and preliminary clinical activity of the trastuzumab and bevacizumab combination, ECOG-ACRIN E1105 trial was developed to determine if the addition of bevacizumab to a chemotherapy and trastuzumab combination for first-line therapy would improve progression-free survival (PFS) in patients with HER2-positive MBC.
Findings: 96 patients were randomized to receive standard first-line chemotherapy and trastuzumab with or without bevacizumab between November 2007 and October 2009, and 93 began protocol therapy.
Background: In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the preclinical and preliminary clinical activity of the trastuzumab and bevacizumab combination, ECOG-ACRIN E1105 trial was developed to determine if the addition of bevacizumab to a chemotherapy and trastuzumab combination for first-line therapy would improve progression-free survival (PFS) in patients with HER2-positive MBC.
Findings: 96 patients were randomized to receive standard first-line chemotherapy and trastuzumab with or without bevacizumab between November 2007 and October 2009, and 93 began protocol therapy.
Article Synopsis
- This study investigates the impact of COVID-19 on female patients with breast cancer, particularly focusing on underrepresented racial/ethnic populations from March 2020 to June 2021 in the US.
- The analysis included 1,383 patients, revealing that older age and certain racial/ethnic groups (such as Black and Asian American/Pacific Islanders) showed higher odds of severe COVID-19 outcomes.
- Key findings noted that factors like worse performance status, pre-existing health conditions, and active cancer significantly contributed to increased severity, while variables like Hispanic ethnicity and anti-cancer therapy type did not impact outcomes as much.
Article Synopsis
- CDK4/6 inhibitors like ribociclib, when combined with a new endocrine therapy (ET), significantly improve progression-free survival (PFS) for patients with hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed on prior therapies.
- In a phase II, double-blind trial, patients who switched their ET and received ribociclib showed a PFS median of 5.29 months, compared to 2.76 months for those on placebo.
- The study highlights the effectiveness of modifying treatment in advanced breast cancer, demonstrating a notable benefit in PFS, with rates at 6 and 12 months being much higher for the ribociclib group.
Article Synopsis
- The study investigates the impact of COVID-19 on female breast cancer patients using a large U.S. registry during 2020-2021, focusing on underrepresented racial/ethnic populations.
- Key findings show that older age, being Black, Asian American/Pacific Islander, and having worse overall health significantly increase the severity of COVID-19 in these patients.
- The overall hospitalization rate was 37% and mortality rate 9%, but these rates varied depending on the active status of breast cancer in patients.
Purpose: To assess health care professionals' perceptions of barriers to the utilization of breast cancer risk assessment tools in the public health setting through a series of one-on-one interviews with health care team members.
Methods: We conducted a cross-sectional qualitative study consisting of one-on-one semistructured telephone interviews with health care team members in the public health setting in the state of Tennessee between May 2020 and October 2020. An iterative inductive-deductive approach was used for qualitative analysis of interview data, resulting in the development of a conceptual framework to depict influences of provider behavior in the utilization of breast cancer risk assessment.
Purpose: The aim of this study was to gather the perspectives of Black women on breast cancer risk assessment through a series of one-on-one interviews.
Methods: The authors conducted a cross-sectional qualitative study consisting of one-on-one semistructured telephone interviews with Black women in Tennessee between September 2020 and November 2020. Guided by the Health Belief Model, qualitative analysis of interview data was performed in an iterative inductive and deductive approach and resulted in the development of a conceptual framework to depict influences on a woman's decision to engage with breast cancer risk assessment.
Importance: Non-Hispanic Black individuals experience a higher burden of COVID-19 than the general population; hence, there is an urgent need to characterize the unique clinical course and outcomes of COVID-19 in Black patients with cancer.
Objective: To investigate racial disparities in severity of COVID-19 presentation, clinical complications, and outcomes between Black patients and non-Hispanic White patients with cancer and COVID-19.
Design, Setting, And Participants: This retrospective cohort study used data from the COVID-19 and Cancer Consortium registry from March 17, 2020, to November 18, 2020, to examine the clinical characteristics and outcomes of COVID-19 in Black patients with cancer.
Article Synopsis
- The COVID-19 pandemic has affected cancer patients differently across various regions in the U.S., showing that these patients are at a higher risk for severe COVID-19 complications.
- This study tracked and analyzed COVID-19 outcomes among cancer patients diagnosed between March and November 2020 across different U.S. census divisions, focusing on factors that may influence their health outcomes.
- Results indicated significant variability in 30-day mortality rates among cancer patients in different centers, ranging from 5.2% to 26.6%, suggesting that geographic location and healthcare center characteristics play a crucial role in these outcomes.